The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-targeted treatment has yielded a notable clinical benefit in patients with HER2-positive breast cancer. However, nearly 50% of patients still suffer disease progression due to resistance to HER2-targeted therapy. After the failure of macrom...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Libin, Shen, Xiabo, Liu, Yiyuan, Gao, Lu, Wu, Jiayi, Yu, Chang, Li, Guangliang, Wang, Xiaojia, Shao, Xiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745359/
https://www.ncbi.nlm.nih.gov/pubmed/36523304
http://dx.doi.org/10.21037/tcr-22-2483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745359/
https://www.ncbi.nlm.nih.gov/pubmed/36523304
http://dx.doi.org/10.21037/tcr-22-2483

Ejemplares similares